Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | Pancreatic Cancer | Biological, Drug, Drug, Drug, Other, Other, Procedure, Procedure, Procedure, Radiation - bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with combination chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: The phase II trial is studying the side effects and how well giving bevacizumab together with gemcitabine, oxaliplatin, fluorouracil, and radiation therapy works in treating patients undergoing surgery for locally advanced pancreatic cancer. | ||
|
Clinicaltrials.gov | Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment | Completed | Unspecified Adult Solid Tumor, Protocol Specific | Drug, Drug, Other, Other, Other, Other, Other, Other, Procedure - hydroxychloroquine, temsirolimus, electron microscopy, high performance liquid chromatography, immunologic technique, laboratory biomarker analysis, mass spectrometry, pharmacological study, autophagy inhibition therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with temsirolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of hydroxychloroquine when given together with temsirolimus in treating patients with metastatic solid tumors that have not responded to treatment. | ||
|
Clinicaltrials.gov | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | Unknown status | Kidney Cancer | Drug, Drug, Genetic, Genetic, Genetic, Genetic, Other, Other, Other, Other, Procedure, Procedure, Procedure - motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well sunitinib works when given before and after surgery in treating patients with stage IV kidney cancer. | ||
|
Clinicaltrials.gov | Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | Completed | Unspecified Adult Solid Tumor, Protocol Specific | Drug, Drug, Genetic, Genetic, Other, Other, Other, Other, Other, Other, Other - hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of hydroxychloroquine when given together with temozolomide in treating patients with metastatic or unresectable solid tumors. | ||
Clinicaltrials.gov | Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura | Terminated | Lung Cancer, Metastatic Cancer | Drug, Drug, Other, Other, Procedure, Procedure - chemotherapy, porfimer sodium, immunohistochemistry staining method, laboratory biomarker analysis, spectroscopy, therapeutic conventional surgery | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy given during surgery works in treating patients with resectable non-small cell lung cancer that has spread to the pleura. | ||
|
Clinicaltrials.gov | Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | Completed | Lung Cancer | Drug, Drug, Drug, Genetic, Other, Other, Procedure, Radiation - cisplatin, etoposide, nelfinavir mesylate, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, radiation therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1/Phase 2 | Interventional | RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Nelfinavir may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving nelfinavir together with radiation therapy, cisplatin, and etoposide may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir when given together with radiation therapy, cisplatin, and etoposide and to see how well they work in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. | ||
|
Clinicaltrials.gov | Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer | Completed | Breast Cancer, Healthy, no Evidence of Disease | Behavioral, Other, Other, Other, Other, Other, Other, Other, Other, Other, Procedure, Procedure, Procedure - exercise intervention, counseling intervention, gas chromatography, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry, physiologic testing, questionnaire administration, survey administration, dual x-ray absorptometry, magnetic resonance imaging, study of high risk factors | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 35 Years | N/A | Interventional | RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer. PURPOSE: This randomized clinical trial is studying how well exercise programs work in healthy young women at increased risk of developing breast cancer. | |
|
Clinicaltrials.gov | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | Completed | Recurrent Melanoma, Stage IV Melanoma | Biological, Biological, Other - CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis | Abramson Cancer Center of the University of Pennsylvania, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma. | ||
|
Clinicaltrials.gov | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | Completed | Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer | Genetic, Other, Procedure, Drug, Other, Other - mutation analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis | Abramson Cancer Center of the University of Pennsylvania, Other | 18 Years - N/A | Observational | Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer. | |||
|
Clinicaltrials.gov | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Withdrawn | Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma | Drug, Other, Other - dovitinib lactate, pharmacological study, laboratory biomarker analysis | Academic and Community Cancer Research United, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. | ||
|
Clinicaltrials.gov | Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV | Completed | Anal Cancer, HIV Infection, Human Papilloma Virus Infection | Procedure, Other, Other, Procedure - comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment | AIDS Malignancy Consortium, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - N/A | N/A | Interventional | This clinical trial studies anal human papillomavirus (HPV) tests in screening for cell changes in the anus in patients with human immunodeficiency virus (HIV). Screening tests may help doctors find cancer cells early and plan better treatment for anal cancer. Completing multiple screening tests may help find the best method for detecting cell changes in the anus. | |
|
Clinicaltrials.gov | PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma | Terminated | Kaposi's Sarcoma | Drug, Genetic, Genetic, Genetic, Other, Other, Other, Procedure - VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy | AIDS Malignancy Consortium, National Cancer Institute (NCI), PTC Therapeutics, The Emmes Company, LLC, Other, NIH, Industry, Industry | 18 Years - 120 Years | Phase 1/Phase 2 | Interventional | RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma. | ||
|
Clinicaltrials.gov | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma | Completed | Lymphoma | Biological, Biological, Biological, Biological, Drug, Drug, Drug, Drug, Other, Other - filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Other, NIH, Industry | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving combination chemotherapy together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with newly diagnosed AIDS-related B-cell non-Hodgkin's lymphoma. | ||
|
Clinicaltrials.gov | Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma | Withdrawn | AIDS-related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma | Drug, Other, Other - gamma secretase inhibitor PF-03084014, pharmacological study, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Other, NIH, Industry | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies the effects, good and bad, of gamma secretase inhibitor PF-03084014 and to see how well it works in treating patients with acquired immune deficiency virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink the tumor. | ||
|
Clinicaltrials.gov | Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma | Completed | Lymphoma, Nonneoplastic Condition | Genetic, Other - polymerase chain reaction, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Other, NIH, Industry | 18 Years - N/A | Observational | RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood and tissue samples from patients with aggressive non-Hodgkin B-cell lymphoma or Hodgkin lymphoma. | |||
|
Clinicaltrials.gov | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | Active, not recruiting | AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Stage III AIDS-related Lymphoma, Stage IV AIDS-related Lymphoma | Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Other - cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, lomustine, etoposide, cyclophosphamide, procarbazine hydrochloride, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Other, NIH, Industry | 18 Years - N/A | Phase 2 | Interventional | This randomized phase II trial studies how well intravenous (IV) chemotherapy or oral chemotherapy works in treating patients with previously untreated stage III-IV human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, lomustine, etoposide, and procarbazine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells | ||
|
Clinicaltrials.gov | Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy | Terminated | Lymphoma, Nonneoplastic Condition | Genetic, Genetic, Other - DNA analysis, RNA analysis, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Other, NIH, Industry | 18 Years - N/A | Observational | RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV. PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy. | |||
|
Clinicaltrials.gov | Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males | Completed | Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition | Biological, Other - quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Merck Sharp & Dohme Corp., AIDS and Cancer Specimen Resource, Other, NIH, Industry, Other, Industry, Other | Male | 13 Years - 26 Years | Phase 2 | Interventional | RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males. | |
|
Clinicaltrials.gov | Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | Recruiting | Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection | Drug, Drug, Other, Other - imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Other, NIH, Industry, Other | 25 Years - N/A | Phase 3 | Interventional | This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions. | ||
|
Clinicaltrials.gov | Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions | Active, not recruiting | Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection | Drug, Drug, Device, Device, Device, Other, Other - imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, San Francisco, Other, NIH, Industry, Other, Other | 35 Years - N/A | Phase 3 | Interventional | This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
